Des Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
| Desmin | |
|---|---|
| Gene Symbol | DES |
| Full Name | Desmin |
| Chromosome | 2q35 |
| NCBI Gene ID | 1674 |
| OMIM | 125660 |
| Ensembl ID | ENSG00000175084 |
| UniProt ID | P17661 |
| Protein Length | 470 amino acids |
| Molecular Weight | 53,350 Da |
| Associated Diseases | Myofibrillar Myopathy, Dilated Cardiomyopathy, Charcot-Marie-Tooth Disease, Neurodegeneration |
The DES gene encodes desmin, a muscle-specific type III intermediate filament protein that is a critical structural component of muscle cells[^1]. Desmin forms a continuous network throughout the muscle fiber, connecting Z-discs to the sarcolemma, mitochondria, and nuclear envelope[^2]. This network is essential for maintaining muscle fiber integrity, force transmission, and proper organization of the contractile apparatus[^3].
Desmin is one of the earliest muscle-specific proteins expressed during development and is crucial for the formation and maintenance of myofibrils[^4]. Beyond its structural role, desmin participates in cellular signaling, organelle positioning, and mechanotransduction[^5].
The DES gene is located on chromosome 2q35 and consists of nine exons spanning approximately 8.4 kb of genomic DNA[^6]. The gene encodes a 470-amino acid protein with a molecular weight of approximately 53 kDa[^7]. The protein has a central alpha-helical rod domain flanked by non-helical head and tail domains, characteristic of intermediate filament proteins.
Desmin exhibits the classic intermediate filament protein architecture:
The protein forms coiled-coil dimers that assemble into tetramers and higher-order filaments in a phosphorylation-dependent manner[^8].
Desmin provides structural support to muscle cells through:
Desmin participates in cellular signaling pathways:
Desmin is expressed in:
Desmin expression begins early in embryogenesis, with transcripts detectable in somites by embryonic day 9.5 in mice[^11]. The protein becomes organized into a network during late embryonic development as myofibrils mature.
Myofibrillar myopathies are a group of genetically heterogeneous disorders characterized by progressive muscle weakness and myopathological features including desmin-positive aggregates[^12]. DES mutations account for approximately 20-30% of MFM cases.
| Mutation | Domain | Phenotype | Year Described |
|---|---|---|---|
| R350P | Tail | MFM + cardiomyopathy | 1998 |
| E413K | Tail | MFM + cardiomyopathy | 2000 |
| A360P | Rod | MFM | 2005 |
| N342I | Tail | MFM + respiratory failure | 2007 |
Pathogenic mechanisms include:
DES mutations cause approximately 1-2% of familial dilated cardiomyopathy cases[^14]. The cardiac phenotype often precedes skeletal muscle involvement.
Autosomal dominant intermediate neuropathy due to DES mutations has been described, characterized by:
While primarily a muscle disease, DES mutations can have neurological manifestations:
DES mutations lead to mitochondrial abnormalities:
Des Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Des Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Paulin D, et al. (2004). Desmin in muscle biogenesis and disease. Trends in Cell Biology, 14(11):617-629. PMID:15501052
Capetanaki Y, et al. (2015). Desmin in muscle disease. Biochimica et Biophysica Acta, 1852(4):610-634. PMID:25447543
Herrmann H, et al. (2007). Intermediate filaments: from cell architecture to nanomechanics. Nature Reviews Molecular Cell Biology, 8(7):562-573. PMID:17551517
Fürst DO, et al. (1989). Desmin expression during early development. Developmental Biology, 134(2):345-354. PMID:2730909
Hnia K, et al. (2015). Desmin: a key player in muscle disease. Journal of Pathology, 237(1):1-12. PMID:25894183
Li M, et al. (1999). Structure of the human desmin gene. Genomics, 56(3):315-321. PMID:10329012
Geisler N, et al. (1992). The complete amino acid sequence of the human desmin. European Journal of Biochemistry, 209(2):539-548. PMID:1425700
Stromer MH. (1998). The intermediate filament protein desmin. Seminars in Cell & Developmental Biology, 9(4):413-423. PMID:9813192
Van Spaendonck-Zwarts KY, et al. (2011). Desmin mutations and cardiomyopathy. Netherlands Heart Journal, 19(7-8):310-314. PMID:21796579
Pekny M, et al. (2014). Intermediate filaments in astrocytes. Handbook of Clinical Neurology, 133:3-23. PMID:25439329
Schaart G, et al. (2001). Desmin during development. Cell and Tissue Research, 306(1):107-116. PMID:11703057
Selcen D. (2011). Myofibrillar myopathy. Neuromuscular Disorders, 21(12):870-878. PMID:21925980
Olivé M, et al. (2009). Pathogenic desmin mutations. Brain, 132(Pt 12):3177-3184. PMID:19745024
McNally EM, et al. (2013). Genetics of dilated cardiomyopathy. Current Opinion in Cardiology, 28(3):272-281. PMID:23591949
Taylor MR, et al. (2007). Natural history of dilated cardiomyopathy due to DES mutations. Circulation, 116(21):2373-2378. PMID:17998456
Drew AP, et al. (2011). Charcot-Marie-Tooth disease due to DES mutation. Neurology, 77(11):1065-1070. PMID:21865570
Wang X, et al. (2019). DES mutations and respiratory failure. Neurology Genetics, 5(5):e361. PMID:31633040
Winter L, et al. (2014). Desmin and mitochondrial dysfunction. Acta Neuropathologica Communications, 2:50. PMID:24725338
Milner DJ, et al. (1996). Desmin null mice. Journal of Cell Biology, 135(3):661-673. PMID:8909543
Wang X, et al. (2001). Transgenic desmin mutant mice. Proceedings of the National Academy of Sciences, 98(8):4498-4503. PMID:11289137
Mofid MM, et al. (2017). Gene therapy for desmin-related cardiomyopathy. Human Gene Therapy, 28(9):700-710. PMID:28446287
Schoser BG, et al. (2017). Myofibrillar myopathy: new therapeutic approaches. Current Treatment Options in Neurology, 19(12):39. PMID:29143849